Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

The purpose of this study is to determine the safety of administering obinutuzumab as a single agent alone and in combination with ifosfamide, carboplatin, and etoposide (ICE) chemotherapy and determine the response rate of this treatment for children, adolescents and young adults (CAYA) with relapsed CD20 positive B-cell Non-Hodgkin Lymphoma (B-NHL).

Trial Details

NCT ID
NCT02393157
Phase
PHASE2
Sponsor
New York Medical College
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Obinutuzumab
  • Liposomal ARA-C
  • Ifosfamide
  • Carboplatin
  • Etoposide
Locations (sample)
  • Valhalla, New York, United States|41.07482,-73.77513

Key Eligibility Criteria

  • Patients in first relapse or primary induction failure CD20 positive B-cell leukemia/lymphoma including:
  • Diffuse Large B-Cell Lymphoma
  • Burkitt Lymphoma
  • High Grade B-cell Lymphoma: Not Otherwise Specified (NOS)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →